Anacor Pharmaceuticals, Inc. Announces GlaxoSmithKline Has Initiated Two Phase 2 Trials of GSK ‘052 in Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that GlaxoSmithKline (GSK) has initiated two separate Phase 2b trials of GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).